When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.
At StockStory, we look beyond the headlines with our independent analysis to determine whether these bearish calls are justified. That said, here is one stock where Wall Street’s pessimism is creating a buying opportunity and two facing legitimate challenges.
Two Stocks to Sell:
Baldwin Insurance Group (BWIN)
Consensus Price Target: $32.93 (3.1% implied return)
Rebranded from BRP Group in May 2024, Baldwin Insurance Group (NASDAQ: BWIN) is an independent insurance distribution company that provides tailored insurance, risk management, and employee benefits solutions to businesses and individuals.
Why Does BWIN Give Us Pause?
- Day-to-day expenses have swelled relative to revenue over the last five years as its adjusted operating margin fell by 8.2 percentage points
- Cash-burning tendencies make us wonder if it can sustainably generate shareholder value
- High net-debt-to-EBITDA ratio of 6× increases the risk of forced asset sales or dilutive financing if operational performance weakens
Baldwin Insurance Group’s stock price of $31.93 implies a valuation ratio of 14x forward P/E. To fully understand why you should be careful with BWIN, check out our full research report (it’s free).
Guardant Health (GH)
Consensus Price Target: $195.81 (9.2% implied return)
Pioneering the field of "liquid biopsy" with technology that can identify cancer-specific genetic mutations from a simple blood draw, Guardant Health (NASDAQ: GH) develops blood tests that detect and monitor cancer by analyzing tumor DNA in the bloodstream, helping doctors make treatment decisions without invasive biopsies.
Why Does GH Fall Short?
- Modest revenue base of $1.18 billion means it has less operating leverage but can also grow faster if it executes the right sales strategy
- Negative free cash flow raises questions about the return timeline for its investments
- EBITDA losses may force it to accept punitive lending terms or high-cost debt
Guardant Health is trading at $179.25 per share, or 15.6x forward price-to-sales. Dive into our free research report to see why there are better opportunities than GH.
One Stock to Watch:
Atlassian (TEAM)
Consensus Price Target: $199.23 (3.8% implied return)
Started by two Australian university friends who funded their startup with credit cards, Atlassian (NASDAQ: TEAM) provides software tools that help teams plan, track, collaborate, and share knowledge across organizations.
Why Does TEAM Stand Out?
- Annual revenue growth of 22.8% over the last two years was superb and indicates its market share is rising
- Winning new contracts that can potentially increase in value as its billings growth has averaged 20.5% over the last year
- Software is difficult to replicate at scale and leads to a best-in-class gross margin of 85.6%
At $192.02 per share, Atlassian trades at 6.6x forward price-to-sales. Is now a good time to buy? Find out in our full research report, it’s free.
Stocks We Like Even More
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
